drugset / Trial / NCT01634295

Efficacy and Safety of CKD-828 to Stage 2 Hypertension

NCT01634295

Phase 3 Completed 103 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg, 2.5/80mg and 5/80mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Timeline

Start
2012-07
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject S-amlodipine Unknown 2.5 mg
Subject S-amlodipine Unknown 5 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg

Indications